Nyxoah S.A. (NYXH) Stock Analysis & Investment Frameworks
Nyxoah S.A. (NYXH) stock analysis on Invetso. Review Nyxoah S.A.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Nyxoah S.A. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Medical - Specialties
- Country: BE
Nyxoah S.A. Key Financial Metrics
- Market Cap: $83.71M
- Revenue: $11.22M
- ROE: -179.71%
- ROIC: -59.89%
- Dividend Yield: N/A
About Nyxoah S.A.
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A. Investment Frameworks
Invetso analyzes Nyxoah S.A. (NYXH) across the following frameworks:
- Nyxoah S.A. 10Y Growth Potential
- Nyxoah S.A. Scenario Analysis
- Nyxoah S.A. Risks & Opportunities
- Nyxoah S.A. Economic Moat
- Nyxoah S.A. Business Model
- Nyxoah S.A. Management
- Nyxoah S.A. SWOT Analysis
- Nyxoah S.A. Porter's 5 Forces
- Nyxoah S.A. PESTLE Analysis
- Nyxoah S.A. ESG Analysis